Cipla Cuts MRP of 28 Cancer Medicines from 9 November 2026: Old vs New Price List

Cipla has issued a revised MRP list for its cancer-care and specialty range. For 28 of the 32 medicines on the list the MRP comes down, and the company's notice says the benefit of the lower MRP is to be passed on to patients from 9 November 2026. For some of them the cut is dramatic: a pack of Dasatrue 70 mg drops from about ₹8,766 to ₹1,858, and Armotraz 1 mg from ₹785 to under ₹150.

Cancer treatment usually runs for months or years, so a change of this size matters to a family's monthly budget. Below is what changes, when, and the full medicine-by-medicine list.

What changes, and from when

• Up to 8 November 2026: the existing MRP applies.
• From 9 November 2026: the revised (lower) MRP applies. Packs printed with the older MRP may still be in the market for a while; Cipla's notice says the benefit of the reduction is to be passed on to patients from this date, so you should not be charged more than the new MRP.
• Four medicines are unchanged: Actemra 80 mg, 200 mg and 400 mg, and Gazyva.

Biggest reductions

• Armotraz 1mg: ₹784.71 → ₹146.78, about 81% lower
• Dasatrue 70mg: ₹8,765.62 → ₹1,858.17, about 79% lower
• Dasatrue 50mg: ₹6,703.12 → ₹2,030.50, about 70% lower
• Erlocip 150mg: ₹9,798.99 → ₹3,448.37, about 65% lower
• Erlocip 100mg: ₹6,759.66 → ₹2,990.13, about 56% lower

Full list: old MRP vs new MRP

Grouped by medicine (salt), with what each one is mainly prescribed for. Every name links to its page on Namo Pharmacy.

Anastrozole: hormone-sensitive breast cancer after menopause

• Armotraz 1mg (10 tablets): ₹784.71 → ₹146.78 (81% lower)

Erlotinib: EGFR-mutation positive lung cancer

• Erlocip 150mg (30 tablets): ₹9,798.99 → ₹3,448.37 (65% lower)
• Erlocip 100mg (30 tablets): ₹6,759.66 → ₹2,990.13 (56% lower)

Everolimus: advanced breast cancer, kidney cancer and neuroendocrine tumours

• Rolimus 10mg (10 tablets): ₹11,434.50 → ₹8,931.30 (22% lower)
• Rolimus 5mg (10 tablets): ₹8,877.92 → ₹6,031.31 (32% lower)

Abiraterone Acetate: advanced prostate cancer

• Xbira 250mg (120 tablets): ₹22,120.30 → ₹11,048.46 (50% lower)
• Xbira 500mg (60 tablets): ₹22,687.50 → ₹12,325.20 (46% lower)

Lenvatinib: thyroid, liver and kidney cancer

• Lenvatol 4mg (10 capsules): ₹1,922.76 → ₹1,304.07 (32% lower)
• Lenvatol 10mg (10 capsules): ₹4,985.00 → ₹3,567.17 (28% lower)

Nintedanib: lung fibrosis (IPF) and, with docetaxel, some lung cancers

• Nintib 100mg (10 capsules): ₹947.08 → ₹834.68 (12% lower)
• Nintib 150mg (10 capsules): ₹1,166.70 → ₹1,008.77 (14% lower)

Tocilizumab: rheumatoid arthritis and giant cell arteritis

• Actemra 162mg (1 prefilled syringe): ₹25,461.00 → ₹20,334.36 (20% lower)

Enzalutamide: advanced prostate cancer

• Xylutide 40mg (4 capsules): ₹1,043.62 → ₹599.64 (43% lower)

Cabozantinib: advanced kidney, liver and thyroid cancer

• Cabotres 20mg (30 tablets): ₹8,765.62 → ₹5,021.85 (43% lower)
• Cabotres 40mg (30 tablets): ₹14,437.50 → ₹8,125.33 (44% lower)

Denosumab: bone complications of cancer

• Denoci Injection (1 vial): ₹35,560.00 → ₹18,772.91 (47% lower)

Palbociclib: HR-positive, HER2-negative advanced breast cancer

• Piciclib 75mg (21 capsules in 3 bottles of 7): ₹5,652.57 → ₹4,074.17 (28% lower)
• Piciclib 100mg (21 capsules in 3 bottles of 7): ₹5,802.32 → ₹4,576.70 (21% lower)
• Piciclib 125mg (21 capsules in 3 bottles of 7): ₹6,438.69 → ₹4,839.99 (25% lower)

Apalutamide: prostate cancer

• Proapaci 60mg (120 tablets): ₹37,139.43 → ₹34,648.28 (7% lower)

Denosumab: osteoporosis and bone loss from cancer hormone therapy

• Denoci OP 60mg (1 prefilled syringe of 1 ml): ₹17,015.62 → ₹9,396.04 (45% lower)
• Denoci 60mg (1 prefilled syringe of 1 ml): ₹17,015.62 → ₹8,375.31 (51% lower)

Xelucip: specialty oncology medicine

• Xelucip 120mg (30 tablets): ₹8,343.75 → ₹7,659.44 (8% lower)

Olaparib: BRCA-mutated ovarian, breast, prostate and pancreatic cancer

• Obparp 150mg (8 tablets): ₹2,208.93 → ₹1,859.38 (16% lower)
• Obparp 100mg (8 tablets): ₹2,062.50 → ₹1,739.25 (16% lower)

Dasatinib: Ph-positive CML and ALL

• Dasatrue 50mg (60 tablets): ₹6,703.12 → ₹2,030.50 (70% lower)
• Dasatrue 70mg (60 tablets): ₹8,765.62 → ₹1,858.17 (79% lower)

Combinib: specialty oncology medicine

• Combinib 250mg (30 tablets): ₹8,228.00 → ₹5,794.75 (30% lower)

Medicines whose MRP stays the same

• Actemra 80mg (1 pack): ₹8,915.00, unchanged
• Actemra 200mg (1 pack): ₹22,281.00, unchanged
• Actemra 400mg (1 pack): ₹44,559.00, unchanged
• Gazyva 1000mg (1 vial): ₹3,41,107.00, unchanged

Should you wait until 9 November to buy?

Never stop or delay a cancer medicine to save money. A missed course can let the disease progress, and that costs far more than any price difference. If you still have enough tablets to last past 9 November, it is reasonable to plan your next purchase for after that date. If you are running short, buy what you need now. And if cost is the real problem, tell your oncologist: there are often patient-support programmes, and sometimes a different pack size or brand can help.

All of these are Schedule H prescription medicines. Many need regular blood tests or other monitoring while you take them, so they must only be used under your specialist's supervision.

Ordering on Namo Pharmacy

You can see the whole range on our Cancer Care page. Add the medicine to your cart and upload a valid prescription from your oncologist; the order is confirmed only after the prescription is verified. The product pages already show the coming MRP next to today's price until 9 November, and switch to the new MRP automatically on that date.

Source: Cipla Ltd revised MRP list for these SKUs, effective 9 November 2026. Prices are MRPs (inclusive of all taxes) as published by the company; the selling price on Namo Pharmacy may be lower.

Medically reviewed by: Neeraj Kathuria, Registered Pharmacist (Reg. No. 3344), AARX Pharmacy, Bhiwadi.